Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....

Less than three months after COVID-19 reached pandemic status, and five since the virus was sequenced, drug development has reached the point where hundreds of clinical trials will soon read out. With a pile of...

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis. Richard Furie, the lead investigator of...

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...

The World Health Organization launched its COVID-19 patent pool Friday facing significant obstacles that include a lack of support from China, the U.K. and the U.S., as well as pushback from leading pharma executives who...

The scientific progress toward finding countermeasures against COVID-19 in the past five months is “unprecedented in the history of the world,” GSK’s Hal Barron said on the latest BioCentury This Week - Special Report podcast . Barron,...

Don’t expect global manufacturing capacity to rapidly fill in for the first few COVID-19 vaccines to market, according to Paul Stoffels. The J&J vice chairman and CSO said it could take over a year for...

Pharma veteran Fabrice Chouraqui is the first new hire at Flagship to take the title of CEO partner, but he likely won’t be the last. Chouraqui will join Flagship Pioneering as he also becomes CEO...

Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities. CEO Carl Hansen...

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...